Revvity Inc vs USA Rare Earth Inc. Class A Common Stock — how do they compare? Revvity Inc trades at $153 (market cap $16.97B), while USA Rare Earth Inc. Class A Common Stock trades at $10.13 (market cap $3.87B). The key difference: Revvity Inc is far larger — about 4.4× USA Rare Earth Inc. Class A Common Stock's market cap, and Revvity Inc pays a 0.18% dividend while USA Rare Earth Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 13 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.
| RVTY | USAR | |
|---|---|---|
Market Cap | $16.97B | $3.87B |
Volume | 1,602,713 | 20,993,390 |
Sector | Health | Basic Materials |
52-Week High | $157.36 | $33.68 |
52-Week Low | $82.26 | $10.32 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $19.29B | $2.35B |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →